American Journal of Respiratory and Critical Care Medicine

Rationale: Adults with cystic fibrosis (CF) are susceptible to hypoxemia, hypercapnia, arousal from sleep, and neurobehavioral impairment. Objectives: We hypothesized that pulmonary exacerbations would adversely affect sleep and neurobehavioral performance. Methods: Patients with exacerbations (cases) had sleep studies and neurobehavioral testing before and after inpatient intravenous therapy. Adults with stable CF underwent the same testing procedures (control subjects). Measurements and Main Results: When clinically stable, cases and control subjects had similar lung function, intelligence, and body mass index. Among cases, treatment of an exacerbation improved lung function, quality of life, mood, sleepiness, and activation. Cases spent more time awake after sleep onset (p = 0.02), less time in REM sleep (p = 0.03), and were more hypoxemic than control subjects when unwell. The severity of hypoxemia correlated with lung function. On admission, cases had slower throughput than control subjects in the serial addition and subtraction task (cases, 16 ± 4, vs. control subjects, 17 ± 3; F[1, 36] = 5.15, p = 0.03) and a slower response time on the digit symbol substitution task (F[1, 36] = 11.91, p = 0.001), which persisted after treatment (F[1, 36] = 8.48, p = 0.006). Cases experienced significant improvements in sleep efficiency, amount of REM sleep, and hypoxia with treatment. Their performance in the serial addition and subtraction task, psychomotor vigilance task, and simulated driving task also improved with treatment. Sex modified the effect of an exacerbation on some aspects of performance. Conclusions: Exacerbations of lung disease in adults with CF adversely affect sleep and tests of neurobehavioral performance regardless of underlying disease severity. The implications for performance in daily life need further evaluation because patients often delay admission to hospital to fulfill study or work commitments.

Information is limited about the effect of an infective exacerbation on sleep and neurobehavioral function in adults with cystic fibrosis (CF). Sleep fragmentation and hypoxemia, which can impair cognitive function in patients with sleep apnea/hypopnea syndrome (13), may worsen in patients with CF during pulmonary exacerbations. Hypoxemia impairs cognitive function in humans at altitude and in patients with severe chronic obstructive pulmonary disease (4). Even a single night of sleep fragmentation makes young, healthy subjects sleepier during the day, impairs their subjective assessment of mood, and decreases mental flexibility and sustained attention (5).

A previous report of neurobehavioral function in adults with CF focused on patients with clinically stable severe lung disease and demonstrated objective neurocognitive impairment and increased daytime sleepiness in these patients when compared with healthy control subjects (6). We hypothesized that patients with CF would be more vulnerable to disrupted sleep architecture, worsening sleep hypoxemia, and impaired cognitive performance during a pulmonary exacerbation than during a period of clinical stability, and would improve with treatment. Because all patients could potentially be susceptible to exacerbation-related sleep and cognitive effects, we studied adults with a wide range of pulmonary function. Some of the results of this study have been previously reported in the form of abstracts (7, 8).

Subjects and Setting

Subjects older than 16 years were recruited from the Adult Cystic Fibrosis Clinic at Royal Prince Alfred Hospital. Informed consent was obtained, and the study was approved by the Central Sydney Ethics Review Committee.

Cases were studied at the beginning and end of a pulmonary exacerbation. Other patients with CF, volunteering to act as “control subjects,” underwent the same testing procedures when in a clinically stable state.

Protocol

Cases answered a validated CF quality-of-life questionnaire (9), underwent polysomnography while breathing room air with evening and early-morning arterial blood gases, also on room air, and had neurobehavioral testing, before and after inpatient treatment of an exacerbation. Further details can be found in the online supplement. Control subjects underwent the same testing procedures on two occasions separated by a period of 10 to 14 days. Neurobehavioral testing was performed either in the afternoon before or on the morning after polysomnography. Twelve cases had neurobehavioral testing performed after spending their first night in hospital. Subjects were tested at the same time of day on each occasion to control for circadian variation in vigilance and alertness. Similar numbers in each group performed the test bout in the afternoon and morning. All subjects were instructed to abstain from alcohol and caffeine-containing drinks for 12 hours before testing.

Sleep studies and arterial blood gases were performed and scored as previously described (10, 11). Total sleep time (TST) minimum average oxyhemoglobin saturation was calculated by averaging the lowest saturation measurement in each 30-second period of sleep.

Intelligence was assessed using the Shipley Institute of Living Scale (12). Spirometry, resting daytime SpO2, and weight were measured before each test bout. Spirometry was performed according to American Thoracic Society guidelines (13).

Neurobehavioral Function

Neurobehavioral function was evaluated using the Neurobehavioral Assessment Battery (University of Pennsylvania) (14) and the AusEd driving simulator (Woolcock Institute for Medical Research, Sydney, Australia) (15). Further details can be found in the online supplement.

Statistical Analysis

Physiologic data are presented as mean ± SD. The Shapiro-Wilk test was used to test for normality. Levene's test for homogeneity of variance was performed. The paired t test or the Wilcoxon signed rank test was used to compare scores obtained at the first (pre) and second (post) study visits within each group. The Student's t test or Mann-Whitney U test for continuous variables and χ2 or Fisher's exact test for categoric variables were used to analyze differences in baseline characteristics between the two groups. Pearson or Spearman correlations were performed. The sample size was calculated a priori to detect a change in arousal frequency of 5/hour during sleep and/or a 200-ms reduction in reaction speed in the driving simulation task for patients with an exacerbation, with a power of 0.80 and a two-sided α of 0.05.

Analysis of covariance was performed to assess the effect of an exacerbation on neurobehavioral and driving simulator performance using PROC GLM in SAS, version 8.2 (SAS Institute, Cary, NC). Age and sex were included as covariates in all neurobehavioral analyses.

Baseline Parameters

When the patients with CF with exacerbations (cases) were in a clinically stable state, the two groups did not differ significantly in terms of age, lung function, education or intelligence levels, body mass indices, and resting daytime SpO2 (Table 1)

TABLE 1. Subject characteristics when cases were in a clinically stable state



Cases

Control Subjects

(n = 22)
(n = 22)
Age, yr26 ± 930 ± 8
Male, %3664
Estimate of IQ, au42 ± 846 ± 8
BMI, kg/m220 ± 222 ± 4
FEV1, % predicted59 ± 2461 ± 26
FVC, % predicted80 ± 2679 ± 22
SpO2, %
96 ± 2
95 ± 2

Definition of abbreviations: au = arbitrary units; BMI = body mass index; IQ = intelligence quotient.

Values are presented as mean ± SD unless otherwise stated.

.

The cases improved their FEV1 percent-predicted (45 ± 20 pretreatment vs. 56 ± 24 posttreatment, p < 0.001), FVC percent-predicted (64 ± 21 pretreatment vs. 80 ± 26 posttreatment, p < 0.001), and body mass index (19.7 ± 2.2 pretreatment vs. 20.1 ± 2.1 posttreatment, p = 0.01) with treatment. There were no significant changes in the control group between study visits. When admitted, cases were more tachypnoeic than control subjects, both while awake and during stage 2 sleep (cases, 26 ± 7, vs. control subjects, 20 ± 5 bpm; p = 0.004). They also spent a greater proportion of sleep time tachycardic (cases, 10 ± 21% of sleep time with heart rate > 100, vs. control subjects, 1 ± 1% of sleep time with heart rate > 100 bpm; p = 0.03). After treatment, the cases' respiratory rates and proportion of sleep time spent tachycardic did not differ from those of control subjects.

The CF Questionnaire

When admitted with an exacerbation, cases had more respiratory symptoms, a worse perception of their health state, and reduced physical functioning and vitality than control subjects. After inpatient treatment, they reported a reduced treatment burden compared with control subjects. The cases demonstrated significant improvements with treatment in 8 of 12 dimensions. No dimension of the CF questionnaire changed significantly among control subjects between study visits (see Table E1 in the online supplement).

Sleep Architecture

The cases spent more time awake after sleep onset than control subjects (p = 0.02) when unwell. They also had reduced percentage of REM sleep (p = 0.03) and spent fewer minutes in REM sleep (p = 0.04). Cases and control subjects had similar numbers of REM sleep bouts, but the cases' REM bouts were shorter. After treatment, cases had a reduced arousal index (p = 0.001) compared with control subjects and a greater amount of slow-wave sleep (p = 0.02; Table 2)

TABLE 2. Sleep architecture in cases and control subjects at first (pre) and second (post) sleep study



Cases (n = 20)

Control Subjects (n = 20)

Pre
Post
p Value
Pre
Post
p Value
TST, min295 ± 96328 ± 720.05325 ± 64346 ± 500.19
Sleep efficiency, %64 ± 1875 ± 15< 0.00173 ± 1180 ± 100.01
Sleep latency, min*42 ± 4032 ± 440.2730 ± 2426 ± 310.15
WASO, min99 ± 4275 ± 500.0268 ± 3964 ± 660.20
NREM RDI*1.0 ± 1.10.8 ± 1.10.532.1 ± 2.92.3 ± 2.80.65
REM RDI*11.8 ± 13.310.4 ± 12.20.6513.2 ± 18.713.4 ± 21.00.77
Total RDI*2.3 ± 2.62.5 ± 3.20.993.6 ± 4.13.7 ± 3.70.77
AH duration, s22 ± 1218 ± 100.2318 ± 718 ± 70.88
Arousal index16 ± 713 ± 40.0217 ± 517 ± 50.57
Stage 1, %*11 ± 610 ± 40.299 ± 510 ± 50.58
REM latency*142 ± 80121 ± 840.07133 ± 85119 ± 910.63
REM sleep, %12 ± 617 ± 6< 0.00116 ± 616 ± 60.97
REM sleep, min38 ± 2156 ± 260.00252 ± 2156 ± 240.42
Slow-wave sleep, %23 ± 1226 ± 80.1922 ± 720 ± 80.12
Slow-wave sleep, min
67 ± 38
92 ± 42
< 0.001
51 ± 18
65 ± 25
0.003

*Nonparametric tests used; Wilcoxon signed rank test for paired comparisons, Mann-Whitney U test for unpaired comparisons.

Value for cases significantly differs from value for control subjects at the equivalent sleep study, p < 0.05.

Significant change between pre- and poststudy nights, p < 0.05.

Definition of abbreviations: AH = apnea hypopnea; NREM = non-REM; RDI = respiratory disturbance index; TST = total sleep time; WASO = wake after sleep onset.

Values are mean ± SD.

.

After treatment of their exacerbation, cases experienced improvements in sleep efficiency, wake after sleep onset, arousal index, time spent in REM sleep, and time spent in slow-wave sleep (Table 2). Control subjects experienced an improvement in sleep efficiency and time in slow-wave sleep on the second study night.

The respiratory disturbance index among both cases and control subjects, on both study nights, comprised mainly hypopneas, with few obstructive apneas. Two control patients who were overweight were found to have sleep apnea/hypopnea syndrome. One control patient had arousals secondary to periodic limb movements. These unexpected findings contributed to the relatively high mean respiratory disturbance indices and arousal indices seen in the control subjects (Table 2).

Gas Exchange

Compared with control subjects, when admitted with an exacerbation, cases had lower minimum nocturnal SpO2, lower TST minimum average SpO2, and spent a greater proportion of TST and REM sleep time with an SpO2 less than 90%. At the completion of treatment, there were no significant differences in these gas exchange variables between cases and control subjects (Table 3)

TABLE 3. Gas exchange variables in cases and control subjects at the first (pre) and second (post) sleep study||



Cases (n = 20)

Control Subjects (n = 20)

Pre
Post
p Value
Pre
Post
p Value
Minimum desaturation84 ± 586 ± 60.1089 ± 489 ± 30.66
TST min av SpO291 ± 493 ± 3< 0.001§94 ± 394 ± 20.88
TST with SpO2 < 90%, %*43 ± 4425 ± 39< 0.001§16 ± 3011 ± 250.04§
REM with SpO2 < 90%, %*40 ± 4630 ± 410.1118 ± 3214 ± 300.35
P.M. PaO2, mm Hg73 ± 1380 ± 130.009§84 ± 12||78 ± 14**0.01§
A.M. PaCO2, mm Hg40 ± 441 ± 50.0844 ± 344 ± 4††0.73
pH
7.43 ± 0.03
7.42 ± 0.02
0.14
7.42 ± 0.02
7.42 ± 0.03
0.63

*Nonparametric tests used; Wilcoxon signed rank test for paired comparisons, Mann-Whitney U test for unpaired comparisons.

Value for cases significantly differs from value for control subjects at the equivalent sleep study, p < 0.05.

n = 17.

§Significant change between pre- and poststudy nights, p < 0.05.

||n = 18.

n = 17.

**n = 16.

††n = 13.

Definition of abbreviation: TST min av SpO2 = total sleep time minimum average SpO2.

.

The treatment of a pulmonary exacerbation resulted in improvements in TST minimum average SpO2 and percentage of TST spent with an SpO2 less than 90%. The evening PaO2 also improved significantly (Table 3). There was no change in morning PaCO2 or pH. In control subjects, the percentage of TST spent with an SpO2 less than 90% improved on the second study night and evening PaO2 worsened.

Neurobehavioral Assessment Battery
Subjective measures.

Among cases, treatment of an exacerbation was associated with improvement of all six subscale components of the profile of mood states (POMS) and in total mood disturbance. There were no changes in the scores of control patients (Table E2).

The treatment of an exacerbation resulted in significant improvements in subjective sleepiness, Visual Analog Scale scores and the “general activation” and “deactivation sleep” components of the activation-deactivation checklist (Table 4)

TABLE 4. Mean scores (± sd) for subjective neurobehavioural assessment battery components for 20 cases and control subjects at the first (pre) and second (post) study visit



Cases

Control Subjects

Pre
Post
p Value
Pre
Post
p Value
Stanford Sleepiness Scale4 ± 1*3 ± 10.01 3 ± 1 3 ± 10.99
Karolinska Sleepiness Scale6 ± 24 ± 2< 0.001 5 ± 2 5 ± 20.69
VAS
 Physically exhausted–energetic31 ± 1217 ± 10< 0.00120 ± 1022 ± 90.32
 Sharp–mentally exhausted28 ± 1217 ± 8< 0.00120 ± 1122 ± 100.29
 Fresh as a daisy–tired to death29 ± 1217 ± 7*< 0.00120 ± 1023 ± 100.08
AD-CL
 General activation 8 ± 4*12 ± 40.00412 ± 511 ± 40.56
 General deactivation13 ± 412 ± 40.5912 ± 413 ± 30.29
 Deactivation sleep15 ± 411 ± 4*0.00113 ± 413 ± 40.69
 High activation
 7 ± 3
 7 ± 2
0.12
 8 ± 4
 7 ± 2
0.07

*After adjustment for age and sex, the value for cases significantly differs from the value for control subjects at the equivalent study visit, p < 0.05.

Significant at p < 0.05.

Definition of abbreviations: AD-CL = activation-deactivation checklist; VAS = Visual Analog Scale.

.

Objective measures.

Cases had slower throughput (number of correct items/minute) than control subjects in the serial addition and subtraction task (SAST) when admitted with an exacerbation (cases, 16 ± 4, vs. control subjects, 17 ± 3; F[1, 36] = 5.15; p = 0.03) and a slower response time on the digit symbol substitution task (F[1, 36] = 11.91, p = 0.001), which persisted after treatment (F[1, 36] = 8.48, p = 0.006). With treatment, cases significantly increased the number of correct responses in the SAST (pretreatment, 41 ± 8, vs. posttreatment, 43 ± 8; p = 0.03) and decreased their response time on the psychomotor vigilance task (pretreatment, 320 ± 76, vs. posttreatment, 300 ± 71 milliseconds; p = 0.03). In the SAST, both groups showed similar improvements in throughput on repeat testing (Table E3).

With two of the neurocognitive tasks, sex significantly modified the effect of an exacerbation. Men with exacerbations had a reduced number of correct items per minute in the SAST compared with women with exacerbations (pretreatment: men, 12 ± 2, vs. women, 17 ± 4; p = 0.003; posttreatment: men, 14 ± 3, vs. women, 18 ± 4). Women had more lapses (no response for > 500 milliseconds) in the psychomotor vigilance task with an exacerbation compared with men (pretreatment: women, 6.5 ± 7.0, vs. men, 0.5 ± 0.8; p = 0.03; posttreatment: women, 3.2 ± 5.8, vs. men, 0.3 ± 0.5).

Driving Simulator Performance

Driving simulator data were obtained from 17 cases and 19 control subjects. Analyses were adjusted for age and sex, and there was no effect modification. Among cases, treatment of an exacerbation improved mean brake response time to the appearance of trucks on the road (pretreatment, 1,237 ± 206, vs. posttreatment, 1,119 ± 201 miiliseconds; p = 0.01). The mean braking response time did not differ significantly between cases and control subjects either when the cases were unwell or after treatment.

There were no differences between cases and control subjects in steering deviation, speed deviation, or number of crashes.

Correlations

Among cases, associations between FEV1 percent-predicted and the three main exacerbation-related effects on sleep (amount of REM sleep, sleep efficiency, hypoxemia) and cognitive function (SAST throughput, digit symbol substitution task response time, psychomotor vigilance task response time) were examined. There was no correlation between FEV1 percent-predicted and sleep efficiency or percentage of REM sleep among cases either on admission or at discharge. However, when cases presented with an exacerbation, there was a strong correlation between percent-predicted FEV1 and TST minimum average SpO2 (r2 = 0.58, p < 0.001), which persisted after treatment. After adjusting for age and intelligence quotient, there was no association between lung function and performance of cognitive tasks.

We have demonstrated that neurobehavioral function and sleep architecture and gas exchange are adversely affected by infective exacerbations and improve with treatment. Disruptions to sleep architecture, including reduced REM sleep, occurred with exacerbations and improved with treatment but were not related to lung function impairment. The extent to which nocturnal hypoxemia worsened with exacerbations was strongly correlated with lung function and, although hypoxemia significantly improved with treatment, it did not reach levels of control subjects by the completion of inpatient treatment. Exacerbations affected performance in tasks assessing reaction speed, concentration, and concrete reasoning. The effect of exacerbations on some tests of cognitive performance differed depending on sex. Our results raise the possibility of a link between the effects of exacerbations on sleep and neurobehavioral function.

A pulmonary exacerbation adversely affected the speed and accuracy with which subjects performed the SAST and the speed with which they performed the digit symbol substitution task. After treatment of their exacerbations, the cases increased their number of correct responses in the SAST and had better response times and fewer lapses in the psychomotor vigilance task. Similarly with the driving task, the braking response times of cases and control subjects were not significantly different, yet the cases were able to significantly improve their response times after treatment, whereas reaction speed of the control subjects remained stable. This suggests that patients with exacerbations, although not noticeably impaired compared with their peers, may not be fulfilling their own cognitive potential.

Sex differences in strategy and performance of computerized neurobehavioral tests are well recognized (16), but there is little information about the differential effects of illness on performance. Two distinct types of solving strategies for neuropsychologic tests have been identified: one, favored by men, aimed for high speed, using a right-hemisphere–type global strategy, and one, favored by women, aimed for high accuracy, using a left-hemisphere–type strategy (17). Previous work has shown that men usually perform faster than women on reaction time tests (16). The fact that our female patients with exacerbations had particularly slow reaction speeds and the male patients with exacerbations displayed reduced accuracy in simple arithmetic would be consistent with the hypothesis that illness increases the vulnerability of patients of each sex to deterioration in tasks in which they are naturally prone to weakness.

Pulmonary exacerbations were associated with less efficient sleep. The time awake after sleep onset and sleep efficiency of the cases improved with treatment and approached values seen in stable control subjects. Treatment improved the cases' arousal index, suggesting that their sleep was more fragmented than usual when they were admitted with an exacerbation. The patients with the worst lung function experienced more severe nocturnal hypoxemia with exacerbations. In some patients, their hypoxemia did not correct to levels approximating those seen in control patients within the 10- to 14-day treatment period. Similar delayed recoveries in other parameters after treatment of an exacerbation have been previously reported (18).

The significant reduction in REM sleep that occurred with exacerbations was not related to lung function impairment. Treatment of the exacerbation increased amounts of both REM and slow-wave sleep, with quantities of REM sleep returning to levels seen in control subjects. Increased coughing may have contributed to the reduction in REM sleep, because protracted coughing in patients with CF has previously been shown to halt progression to REM sleep (19). Somnogenic acute-phase cytokines, interleukin 1β, interleukin 6, and tumor necrosis factor α, are elevated during exacerbations in patients with CF (18, 20), and increase non-REM sleep intensity at the expense of REM sleep (21). Thus, the REM sleep reduction would also be consistent with an acute response to an infectious stimulus. The increase in slow-wave sleep may have represented recovery from sleep deprivation associated with hospitalization for exacerbations (22). Arousal threshold is increased in slow-wave sleep (23). This may have contributed to the reduced arousal index seen in the cases on their second study night.

Although small numbers precluded direct correlation of neurobehavioral function scores with objective measures of sleep fragmentation or hypoxia, our findings are consistent with a possible link between the sleep and cognitive effects of exacerbations. The subjective components of the Neurobehavioral Assessment Battery relating to feelings of sleepiness, exhaustion, and activation improved markedly after treatment. The SAST is a test of concentration and concrete reasoning, whereas the digit symbol substitution task tests speed, accuracy and concentration. They are sensitive to sleep deprivation, fragmentation, and hypoxic injury (24). The psychomotor vigilance task and driving task are vigilance tasks, designed to measure sustained, focused attention. They assess reaction time, which is sensitive to partial or complete sleep deprivation (25). The absolute amount of REM sleep has also been correlated with intellectual functioning (26) and declines markedly in the case of organic brain dysfunctions of the elderly (27). In addition, both sleep fragmentation and hypoxemia are well-recognized contributors to impaired cognitive function and increased daytime sleepiness in patients with sleep apnea/hypopnea syndrome (1). The possibility of a similar link in patients with CF warrants further study.

Strengths of our study included the presence of a control group of patients with stable CF and our attempt to control for noncognitive influences on test results. Results from both spirometry and the CF questionnaire suggest that patients with CF with exacerbations were successfully differentiated from those without, which is not always straightforward, given the difficulty of accurately defining an exacerbation (2831). The control group allowed first-night effects on sleep and improvements in cognitive tests because of familiarity or practice to be differentiated from true effects related to the exacerbation and its treatment. Medications, nutritional supplements, and intensity of physiotherapy also have the potential to influence sleep and would have varied slightly between the two groups. Within groups, these factors were similar on both study nights and are therefore unlikely to have influenced differences demonstrated between Study Nights 1 and 2. Multiple between-group comparisons without adjustment for multiple analyses can be justified in an exploratory study such as this one (32). However, the possibility of type I error must be considered, and confirmatory studies doing multiple comparisons would require the use of a more conservative p value (32).

Some neurocognitive and driving simulator variables were not normally distributed. In these cases, Levene's test for homogeneity of variance was performed and was nonsignificant. Given equal variances and equal sample sizes, analysis of covariance is fairly robust, even without fulfillment of the assumption of normality. Limitations to neurobehavioral testing using a battery of cognitive tests include the following: the adequacy of the theory that the tests used represent valid neurocognitive constructs, the potential for test–retest and ceiling–floor effects, and subject motivation (2).

The crucial question arising from this study concerns the clinical relevance of these quantitatively small performance decrements to patients' day-to-day lives. In subjects with sleep apnea/hypopnea syndrome, deficits in cognitive tests of executive function consistently translate into complaints of inattention, impulsivity, and emotional lability in children and declining occupational, interpersonal, or cognitive functioning in adults (2). In children with CF, long-term nocturnal oxygen therapy improves school and work attendance (33), highlighting the possibility that cognitive impairment may be amenable to treatment. We did not examine the impact of exacerbations on activities relevant to young adults with CF, including school and examination performance, work productivity and safety, and on-road driving ability. This is an important direction for future study.

We have demonstrated that exacerbations of lung disease in young adults with CF adversely affect sleep and neurobehavioral performance, regardless of underlying disease severity. These results could have important implications for performance in daily life, because patients often delay admission to hospital to fulfill study or work commitments.

The authors thank Dr. Kai Sing Lo for statistical advice, Professor David Dinges for providing the Neurobehavioral Assessment Battery software, and David Joffe, Ben Constable, and Heather Engleman for provision of the AusEd software.

1. Greenberg GD, Watson RK, Deptula D. Neuropsychological dysfunction in sleep apnea. Sleep 1987;10:254–262.
2. Beebe D, Gozal D. Obstructive sleep apnea and the prefrontal cortex: towards a comprehensive model linking nocturnal upper airway obstruction to daytime cognitive and behavioral deficits. J Sleep Res 2002;11:1–16.
3. Macey P, Henderson L, Macey K, Alger J, Frysinger R, Woo M, Harper R, Yan-Go F, Harper R. Brain morphology associated with obstructive sleep apnea. Am J Respir Crit Care Med 2002;166:1382–1387.
4. Stuss D, Peterkin I, Guzman D, Guzman C, Troyer A. Chronic obstructive pulmonary disease: effects of hypoxia on neurological and neuropsychological measures. J Clin Exp Neuropsychol 1997;19:515–524.
5. Martin S, Engleman H, Deary I, Douglas N. The effect of sleep fragmentation on daytime function. Am J Respir Crit Care Med 1996;153:1328–1332.
6. Dancey DR, Tullis D, Heslegrave R, Thornley K, Hanly P. Sleep quality and daytime function in adults with cystic fibrosis and severe lung disease. Eur Respir J 2002;19:504–510.
7. Dobbin CJ, Milross M, Norman M, Piper AJ, Grunstein RR, Bye P. The effects of a pulmonary exacerbation on sleep in adult patients with cystic fibrosis: a pilot study [abstract]. Am J Respir Crit Care Med 2002;165:A286.
8. Dobbin CJ, Bartlett D, Grunstein R, Bye PT. Acute deterioration in neuropsychological function during a pulmonary exacerbation in adults with cystic fibrosis. Pediatr Pulmonol 2003;362:A506.
9. Quittner A, Buu A, Watrous M, Davis M. Cystic Fibrosis Questionnaire (CFQ): a health related quality of life measure. Bethesda, MD: Cystic Fibrosis Foundation; 2000.
10. Milross MA, Piper AJ, Norman M, Becker HF, Willson GN, Grunstein RR, Sullivan CE, Bye PTP. Low flow oxygen and bilevel ventilatory support: effects on ventilation during sleep in cystic fibrosis. Am J Respir Crit Care Med 2001;163:129–134.
11. Milross MA, Piper AJ, Norman M, Grunstein RR, Sullivan CE, Bye PTP. Predicting oxygen desaturation during sleep in patients with cystic fibrosis. Chest 2001;120:1239–1245.
12. Zachary R. Shipley Institute of Living Scale, revised. Los Angeles, CA: Western Psychological Services; 1991.
13. American Thoracic Society. American Thoracic Society statement on standardization of spirometry: 1994 update. Am J Respir Crit Care Med 1995;152:1107–1136.
14. Powell JW, Dinges DF. Operating notes for the computerized performance test battery: NAB: Neurobehavioural Assessment Battery. Philadelphia, PA: Unit for Experimental Psychiatry, University of Pennsylvania School of Medicine; 1988.
15. Banks S, Catchside P, Lack L, Grunstein R, McEvoy D. Low levels of alcohol impair driving simulator performance and reduce perception of crash risk in sleep restricted subjects. Sleep 2004;27:1063–1067.
16. Meurling A, Tonning-Olsson I, Levander S. Sex differences in strategy and performance on computerized neuropsychological tests as related to gender identity and age at puberty. Scand J Psychol 2000;41:81–90.
17. Wirsen Meurling A, Levander S. Dimensionality of skill and strategy measures in a computerized perceptual maze test. Research reports from Department of Psychiatry and Behavioural Medicine. Trondheim, Norway: University of Trondheim; 1994.
18. Aris RM, Stephens AR, Ontjes DA, Denene Blackwood A, Lark RK, Hensler MB, Neuringer IP, Lester GE. Adverse alterations in bone metabolism are associated with lung infection in adults with cystic fibrosis. Am J Respir Crit Care Med 2000;162:1674–1678.
19. Stokes DC, McBride JT, Wall MA, Erba G, Strieder DJ. Sleep hypoxemia in young adults with cystic fibrosis. Am J Dis Child 1980;134:741–743.
20. Nixon LS, Yung B, Bell SC, Elborn JS, Shale DJ. Circulating immunoreactive interleukin-6 in cystic fibrosis. Am J Respir Crit Care Med 1998;157:1764–1769.
21. Krueger JM, Majde JA. Humoral links between sleep and the immune system: research issues. Ann N Y Acad Sci 2003;992:9–20.
22. Vgontzas AN, Mastorakos G, Bixler EO, Kales A, Gold PW, Chrousos GP. Sleep deprivation effects on the activity of the hypothalamic-pituitary-adrenal and growth axes: potential clinical implications. Clin Endocrinol 1999;51:205–215.
23. Berry R, Bonnet M, Light R. Effect of ethanol on the arousal response to airway occlusion during sleep in normal subjects. Am Rev Respir Dis 1992;145:445–452.
24. Saunders D. A factor analysis of the information and arithmetic items of the WAIS. Psychol Rep 1960;6:367–383.
25. Dinges DF, Pack F, Williams K, Gillen A, Powell JW, Ott GE, Aptowitcz A, Pack A. Cumulative sleepiness, mood disturbance, and psychomotor vigilance performance decrements during a week of sleep restricted to 4–5 hours per night. Sleep 1997;20:267–277.
26. Verstraeten E, Cluydts R, Verbraecken J, De Roeck J. Neuropsychological functioning and determinants of morning alertness in patients with obstructive sleep apnea syndrome. J Int Neuropsychol Soc 1996;2:306–314.
27. Carskadon MA, Dement WC. Normal human sleep: an overview. In: Kryger M, Roth T, Dement W, editors. Principles and practice of sleep medicine, 2nd ed. Philadelphia, PA: W.B. Saunders; 1994.
28. Dakin C, Henry RL, Field P, Morton J. Defining an exacerbation of pulmonary disease in cystic fibrosis. Pediatr Pulmonol 2001;31:436–442.
29. Kanga J, Kuhn R, Craigmyle L, Haverstock D, Church D. Cystic fibrosis clinical score: a new scoring system to evaluate acute pulmonary exacerbation. Clin Ther 1999;21:1343–1356.
30. Rosenfeld M, Emerson J, Williams-Warren J, Pepe M, Smith A, Montgomery AB, Ramsey B. Defining a pulmonary exacerbation in cystic fibrosis. J Pediatr 2001;139:359–365.
31. Wood RE. What is a “pulmonary exacerbation” in cystic fibrosis? J Pediatr 1987;111:907–913.
32. Bender R, Lange S. Adjusting for multiple testing: when and how? J Clin Epidemiol 2001;54:343–349.
33. Zinman R, Corey M, Coates AL, Canny GJ, Conolly J, Levison H, Beaudry PH. Nocturnal home oxygen in the treatment of hypoxemic cystic fibrosis patients. J Pediatr 1989;144:368–377.
Correspondence and requests for reprints should be addressed to Catherine Dobbin, M.B.B.S. M.Med., Department of Respiratory Medicine, E 11 West, Royal Prince Alfred Hospital, Missenden Road, Sydney, NSW 2050, Australia. E-mail:

Related

No related items
American Journal of Respiratory and Critical Care Medicine
172
1

Click to see any corrections or updates and to confirm this is the authentic version of record